UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 26, 2012
MELA Sciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 000-51481 | 13-3986004 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
50 Buckhout Street, Suite 1 Irvington, New York |
10533 | |||
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code (914) 591-3783
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 Submission of Matters to a Vote of Security Holders
The 2012 Annual Meeting of Stockholders (the Annual Meeting) of MELA Sciences, Inc. (the Company) was held on April 26, 2012.
The Companys stockholders voted on two proposals as follows: to elect Company directors for the ensuing year (Proposal 1); and to ratify the selection by the Audit Committee of the Companys Board of Directors of EisnerAmper LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2012 (Proposal 2).
All nominees for election to the Board of Directors were elected to serve until the 2013 Annual Meeting of Stockholders and until their respective successors are elected and qualified, or until such directors earlier death, resignation or removal. The stockholders ratified Proposal 2. The number of votes cast for, against or withheld and the number of abstentions and broker non-votes with respect to each Proposal is set forth below.
Proposal 1 | Shares For | Shares Withheld | Broker Non-Votes | |||||||||
Joseph V. Gulfo, MD |
8,603,902 | 468,311 | 16,676,567 | |||||||||
Robert Coradini |
8,596,947 | 475,266 | 16,676,567 | |||||||||
Anne Egger |
8,552,372 | 519,841 | 16,676,567 | |||||||||
Mark Fabiani |
8,569,798 | 502,415 | 16,676,567 | |||||||||
John Goddard |
8,582,997 | 489,216 | 16,676,567 | |||||||||
Mindy Meads |
8,549,537 | 522,676 | 16,676,567 | |||||||||
David K. Stone |
8,384,512 | 687,701 | 16,676,567 | |||||||||
LuAnn Via |
8,373,159 | 699,054 | 16,676,567 |
Shares For | Shares Against | Shares Abstaining | Broker Non-Votes | |||||||||||||
Proposal 2 |
25,369,902 | 289,394 | 89,484 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MELA Sciences, Inc. | ||||||
Date: April 27, 2012 | By: | /s/ Richard Steinhart | ||||
Name: Richard Steinhart | ||||||
Title: Chief Financial Officer |